Gadeta

Gadeta

Gadeta is a biotechnology company developing immunotherapies for treating cancer.

Gadeta is a company that works with T cell receptors in order to make treatments for advanced malignancies. The company was founded by Dr. Mark de Boer and Dr. Jurgen Kuball, in 2015, in Utrecht, Utrecht, The Netherlands.

The company works with hematological and solid tumor cells to discover treatments to combat malignant cancers. Gadeta has created therapeutics with the potential for combating and destroying both blood related and solid cancer. The cells they use are known as TEGs, standing for T-cells engineered to Express a defined Gamma delta TCR (TEGs). Their process uses cells that are carriers with high proliferation activity, and adds them to optimized for killing malignant cells, provide GMP grade lentrival gene transfers, make an enrichment of engineered immune cells in a closed system, which then creates a metabolic targeting of the cancer stem cell.

Gadeta's technology platform is based on the founder Dr. Jurgen Huball's discovery, and utilizes receptors displayed in anti-cancer reactivity to sense metabolic changes in cancer cells.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Gadeta Series A round, March 2016
7,000,000
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Dr. Mark de Boer

Dr. Tolleiv Trimborn

Marco Londei

Further reading

Title
Author
Link
Type
Date

Gilead brings Medicxi’s tiny Gadeta into the cell therapy fold, hunting a way to pick the lock on solid tumors

John Carroll

Web

Gilead’s Kite and Netherlands’ Gadeta Ink Strategic T-Cell Collaboration

Mark Terry

Web

Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors

Business Wire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Gadeta

Dr. Mark de Boer

Utrecht, Utrecht, The Netherlands

Immunotherapies

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.